|
Eli Lilly And Company (LLY) |
|
|
|
LLY's Net Income Growth by Quarter and Year
Eli Lilly And's Net Income results by quarter and year
Select the Comparisons :
|
|
Select the Ratio:
|
|
LLY Net Income (in millions $) |
FY 2022 |
FY 2021 |
FY 2020 |
FY 2019 |
IV Quarter |
December |
1,937.70
|
1,726.10
|
2,116.80
|
1,495.70
|
III Quarter |
September |
1,451.70
|
1,110.10
|
1,208.40
|
1,253.90
|
II Quarter |
June |
952.50
|
1,390.20
|
1,412.00
|
1,327.20
|
I Quarter |
March |
1,902.90
|
1,355.30
|
1,456.50
|
4,241.60
|
FY |
|
6,244.80
|
5,581.70
|
6,193.70
|
8,318.40
|
LLY Net Income fourth quarter 2022 Y/Y Growth Comment |
Eli Lilly And Company achieved in the fourth quarter 2022, above Company average Net Income increase of 12.26% year on year, to $ 1,937.70 millions.
Looking into fourth quarter 2022 results within Major Pharmaceutical Preparations industry 15 other companies have achieved higher Net Income growth. While Eli Lilly And Company' s Net Income growth of 12.26% ranks overall at the positon no. 894 in the fourth quarter 2022.
|
LLY Net Income ( Y/Y Growth %) |
2022
|
2021 |
2020 |
2019 |
IV Quarter |
December |
12.26 % |
-18.46 % |
41.53 % |
383.26 % |
III Quarter |
September |
30.77 % |
-8.13 % |
-3.63 % |
9.08 % |
II Quarter |
June |
-31.48 % |
-1.54 % |
6.39 % |
- |
I Quarter |
March |
40.4 % |
-6.95 % |
-65.66 % |
248.41 % |
FY |
|
11.88 % |
-9.88 % |
-25.54 % |
244.23 % |
LLY Net Income (Quarter on Quarter Growth %) |
2022
|
2021 |
2020 |
2019 |
IV Quarter |
December |
33.48 % |
55.49 % |
75.17 % |
19.28 % |
III Quarter |
September |
52.41 % |
-20.15 % |
-14.42 % |
-5.52 % |
II Quarter |
June |
-49.94 % |
2.58 % |
-3.06 % |
-68.71 % |
I Quarter |
March |
10.24 % |
-35.97 % |
-2.62 % |
1270.47 % |
FY (Year on Year) |
|
11.88 % |
-9.88 % |
-25.54 % |
244.23 % |
Net Income Y/Y Growth Statistics |
High |
Average |
Low |
125.15 % |
3.82 % |
-36.59 % |
(Mar 31 2019) |
|
(Sep. 30. 2008) |
|
Net Income Y/Y Growth Statistics |
High |
Average |
Low |
125.15 % |
3.82 % |
-36.59 % |
(Mar 31 2019) |
|
(Sep. 30. 2008) |
|
Net Income by Quarter for the Fiscal Years 2019, 2020, 2021, 2022 |
Eli Lilly And's Q/Q Net Income Growth
Net Income Q/Q Growth Statistics |
High |
Average |
Low |
1270.47 % |
26.1 % |
-84.86 % |
(Mar 31 2019) |
|
|
LLY's IV. Quarter Q/Q Net Income Comment |
Eli Lilly And Company achieved in the IV. Quarter 2022 above company average sequential Net Income jump of 33.48%, to $ 1,937.70 millions, from $1,451.70 millions in the third quarter.
Within Major Pharmaceutical Preparations industry 9 other companies have achieved higher Net Income quarter on quarter growth. While Eli Lilly And's Net Income growth quarter on quarter, overall rank is 447. |
|
|
Net Income Q/Q Growth Statistics |
High |
Average |
Low |
1270.47 % |
26.1 % |
-84.86 % |
(Mar 31 2019) |
|
|
LLY's IV. Quarter Q/Q Net Income Comment |
Eli Lilly And Company achieved in the IV. Quarter 2022 above company average sequential Net Income jump of 33.48%, to $ 1,937.70 millions, from $1,451.70 millions in the third quarter.
Within Major Pharmaceutical Preparations industry 9 other companies have achieved higher Net Income quarter on quarter growth. While Eli Lilly And's Net Income growth quarter on quarter, overall rank is 447. |
|
Eli Lilly And's 12 Months Net Income Growth Year on Year
Net Income TTM Growth |
12 Months Ending (Dec 31 2022) |
12 Months Ending (Sep 30 2022) |
12 Months Ending (Jun 30 2022) |
12 Months Ending (Mar 31 2022) |
12 Months Ending (Dec 31 2021) |
Cumulative Net Income 12 Months Ending |
$ 6,244.80 |
$ 6,033.20 |
$ 5,691.60 |
$ 6,129.30 |
$ 5,581.70 |
Y / Y Net Income Growth (TTM) |
11.88 % |
1.02 % |
-6.24 % |
0.6 % |
-9.88 % |
Year on Year Net Income Growth Overall
Ranking |
# 811 |
# 1213 |
# 1357 |
# 446 |
# 1376 |
Seqeuential Net Income Change (TTM) |
3.51 % |
6 % |
-7.14 % |
9.81 % |
-6.54 % |
Seq. Net Income Growth (TTM) Overall
Ranking |
# 894 |
# 205 |
# 1251 |
# 835 |
# 263 |
Cumulative Net Income growth
Comment |
Although Eli Lilly And's Annual Net Income growth year on year were below company's average 39.32% , Net Income announced in the Dec 31 2022 period, show improvement in Net Income trend, to cumulative trailing twelve month growth of 11.88% year on year, from 1.02% in Sep 30 2022.
In the Healthcare sector 61 other companies have achieved higher trailing twelve month Net Income growth. While Total ranking has impoved so far to 811, from total ranking in previous quarter at 1213. |
Net Income TTM Q/Q Growth Statistics |
High |
Average |
Low |
125.15 % |
3.82 % |
-36.59 % |
|
|
|
|
|
Net Income TTM Y/Y Growth Statistics |
High |
Average |
Low |
1484.58 % |
39.32 % |
-79.77 % |
|
|
|
Net Income TTM Q/Q Growth Company Ranking |
Within: |
No. |
Industry |
# 16 |
Sector |
# 59 |
S&P 500 |
# 894 |
|
Cumulative Net Income growth
Comment |
Although Eli Lilly And's Annual Net Income growth year on year were below company's average 39.32% , Net Income announced in the Dec 31 2022 period, show improvement in Net Income trend, to cumulative trailing twelve month growth of 11.88% year on year, from 1.02% in Sep 30 2022.
In the Healthcare sector 61 other companies have achieved higher trailing twelve month Net Income growth. While Total ranking has impoved so far to 811, from total ranking in previous quarter at 1213. |
Net Income TTM Q/Q Growth Statistics |
High |
Average |
Low |
125.15 % |
3.82 % |
-36.59 % |
|
|
|
Net Income TTM Y/Y Growth Statistics |
High |
Average |
Low |
1484.58 % |
39.32 % |
-79.77 % |
|
|
|
Net Income TTM Q/Q Growth Company Ranking |
Within: |
No. |
Industry |
# 16 |
Sector |
# 59 |
S&P 500 |
# 894 |
|